We are thrilled to announce Kai Touw, Point-of-Care Site Manager at Galapagos, as one of the keynote speakers. He will be giving a lecture during Single-Use Event 2024 about the Galapagos decentralized CAR-T manufacturing platform.

Kai Touw is a motivated and enthusiastic bridge builder between technological progress and the pharmaceutical industry with over 10 years of experience within the sector.

About Galapagos’ T-cell manufacturing platform

Galapagos’ decentralized, innovative T-cell manufacturing platform has the potential for the administration of fresh, fit cells within a median vein-to-vein time of seven days, greater physician control and improved patient experience. The platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control testing and release strategy.

About Galapagos

Galapagos is a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, they synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, cell therapies, and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized T-cell manufacturing network, they are committed to challenging the status quo and delivering results for their patients, employees and shareholders.